iGan Partners Leads Seed+ Financing for Cosm Medical to Advance Personalized Gynecological Devices
Cosm's flagship platform, GynethoticsTM, combines medical imaging, AI-driven design software, and 3D printing to create custom vaginal devices – starting with pessaries – tailored to each patient's unique anatomy and needs. The solution addresses a widespread but underserved women's health issue: pelvic floor disorders, which affect up to half of all women in their lifetime.
'Cosm is modernizing a long-overlooked space in women's health through a personalized, data-driven platform grounded in precision care,' said Sam Ifergan, Founding Partner at iGan Partners. 'We're excited to support their mission to improve outcomes and quality of life for millions of women.'
'At Cosm, we're not just building a product—we're redefining an entire category of women's health. Our Gynethotics™ platform is more than just technology; it's a commitment to precision, personalization, and dignity in care. With the support of iGan Partners and our investors, we're accelerating a future where women are no longer underserved – where every solution is tailored, and true innovation means changing lives. This is just the beginning.' – Derek Sham, Founder & CEO of Cosm Medical.
'We were impressed with Derek's experience in commercializing medical devices, as well as COSM's extraordinary team, depth of intellectual property and thoughtfulness of the go-to-market strategy, said Olivia Hornby, Managing Partner at Spring Impact Capital. 'As impact investors, we were excited by COSM's mission of building customized and data centric Gynethotics solutions – providing better care for the huge percentage of women who suffer from pelvic floor disorders.
GynethoticsTM pessaries are approved for sale in both Canada and the U.S., and Cosm is actively expanding its presence across North America. The company is also building its clinical dataset and advancing its product pipeline to support new applications beyond pessary support, including postpartum and post-surgical recovery.
About Cosm Medical
Cosm Medical is a medical device company developing a hardware and software platform to personalize the treatment of pelvic floor disorders (PFDs), such as incontinence and pelvic organ prolapse. Its first product, GynethoticsTM, is a made-to-measure gynecological prosthetics platform that combines imaging, AI, and 3D printing to improve pessary performance, enhance patient comfort, and reduce complications. Cosm is redefining care for a long-overlooked area of women's health through precision medicine and digital innovation. Learn more at https://www.cosm.care/
About iGan Partners
iGan Partners is a North American venture capital firm focused on investing in emerging leaders in medical technology and digital health. We partner with founders building transformative solutions to improve patient outcomes, reduce system inefficiencies, and enable the future of data-driven care. iGan provides capital and strategic support to early commercial-stage companies across MedTech, digital health, diagnostics, and health IT. Our team brings deep sector expertise, a strong cross-border network, and a track record of scaling healthcare ventures from early growth to successful exit. Learn more at https://iganpartners.com/
View original content to download multimedia: https://www.prnewswire.com/news-releases/igan-partners-leads-seed-financing-for-cosm-medical-to-advance-personalized-gynecological-devices-302473852.html
SOURCE iGan Partners
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
MiRus Siegel™ TAVR US Early Feasibility Study (EFS) 30 Day Results Presented at NY Valves Meeting
ATLANTA, July 2, 2025 /PRNewswire/ -- The MiRus Siegel™ Valve was featured in three podium presentations at the NY Valves meeting last week. Pradeep K. Yadav MD, Piedmont Heart Institute, Atlanta and Raj R. Makkar MD, Cedars Sinai Heart Institute, Los Angeles presented patient case studies and the 30 day results of US Early Feasibility Study (EFS). In the US EFS, 15 patients with severe, symptomatic aortic stenosis (AS) were treated at Piedmont, Cedars Sinai, Stanford, Mayo Clinic and Naples. At 30 days, there were no deaths, strokes or re-hospitalizations. No patients had vascular complications, PVL (> moderate) or required a permanent pacemaker. Core lab echocardiographic data demonstrated a mean gradient of 6.3 mmHg, and valve area of 2.8 cm2 . The Siegel valve represents several firsts in TAVR: 8 French delivery sheath allowing less invasive procedures and broader patient access, particularly for women; the only Nickel-free THV allowing treatment of the 20% of Americans suffering from Nickel allergies; precise delivery due to lack of foreshortening and intrinsic commissural alignment; dry porcine pericardial leaflets with anti-calcification treatment and with the valve pre-mounted on the balloon. 'This is the first TAVR to have no foreshortening during implantation and along with small vascular access, makes it very user friendly and should also lead to fewer pacemakers and vascular complications' commented Pradeep K. Yadav, MD. 'The lack of nickel is also very appealing – we were able to treat a patient with severe nickel and cobalt allergy.' The combination of low delivery system profile and excellent hemodynamics is made feasible by the unique properties of the Rhenium alloys pioneered by MiRus including high yield strength, fatigue resistance and minimal recoil. 'The gradients and valve areas with the Siegel valve are outstanding' stated Raj R. Makkar, MD. 'Valve placement is very precise and allows us to protect the conduction system – one of our patients was quite elderly with pre-existing conduction system injury and we were able to replace his valve without having to place a permanent pacemaker.' About MiRus, LLC. MiRus is a life sciences company headquartered in Marietta, Georgia that has developed and is commercializing proprietary novel biomaterials, implants and procedural solutions for the treatment of spine, orthopaedic and structural heart disease. Inspired by the pioneering material science of NASA for rocket engines, MiRus has created Rhenium based medical alloys that are transforming medicine by making surgeries less invasive and implants safer and more durable. Find out more information about MiRus at Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company's products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements. The Siegel TAVR system is an investigational device and not FDA approved. * MiRus® , Siegel™ are all trademarks of MiRus, LLC. Contact: Pam Cowart VP of Clinical Affairs [email protected] 770-861-4804 View original content to download multimedia: SOURCE MiRus
Yahoo
2 hours ago
- Yahoo
Joveo Recognized as Strategic Challenger in the 2025 Fosway 9-Grid™ for Talent Acquisition
MENLO PARK, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Joveo, the global leader in AI-led, high-performance recruitment marketing, has been recognized as a Strategic Challenger in the 2025 Fosway Group 9-Grid™ for Talent Acquisition. This recognition underscores Joveo's innovative approach and unwavering commitment to reshaping the future of recruitment with cutting-edge technology and data-driven solutions. The Fosway Group 9-Grid™, a well-regarded market analysis model, evaluates providers on their potential, performance, market presence, trajectory, and total cost of ownership. According to Fosway, Strategic Challengers 'provide solid performance with solutions that have a richer and broader suite of capability than most other solutions in the Fosway 9-Grid™.' Joveo's placement in this category highlights the company's growing influence, strong capabilities, and proven success within the talent acquisition ecosystem. 'Market conditions remain challenging for many TA solution providers, mainly due to the confluence of technological change and a high concentration of candidates,' said Dr. Sven Elbert, Head of Analyst Services at Fosway Group. 'Despite this, growth in recruitment marketing continues apace with companies like Joveo still innovating and winning business. We congratulate them on their move to Strategic Challenger this year.' 'This recognition reinforces what we've known all along – there's a better, smarter way to hire,' said Kshitij Jain, Founder and CEO of Joveo. 'To us, it's about attracting the right talent and optimizing their experience to source the best fit. We're not just improving talent acquisition – we're rebuilding it from the ground up with AI at the core. Our platform delivers the efficiency, personalization, and measurable ROI that traditional methods can't match. We're here to challenge the status quo and redefine what great recruiting looks like.' Joveo's placement in the 2025 9-Grid™ reflects the company's technology leadership, rapid growth, global expansion, and continuous investment in AI to streamline and optimize recruiting. The recognition also highlights the strong partnerships Joveo has cultivated with leading employers and applicant tracking systems, and the tangible hiring outcomes delivered through its solutions. As Joveo continues to challenge the status quo, the company remains focused on delivering scalable, future-ready solutions that address the evolving needs of talent acquisition teams across industries and geographies. To learn more about Joveo's award-winning platform and solutions, visit About Joveo As the global leader in AI-powered, high-performance recruitment marketing, Joveo is transforming talent attraction and recruitment media buying for the world's largest employers, staffing firms, RPOs, and media agencies. The Joveo platform enables businesses to attract, source, engage, and hire the best candidates on time and within budget. Powering millions of jobs every day, Joveo's AI-led recruitment marketing platform uses advanced data science and machine learning to dynamically manage and optimize talent sourcing and applications across all online channels, while providing real-time insights at every step of the job seeker journey, from click to hire. For more information about Joveo's award-winning platform, visit Contact:Heather van WerkhoovenSr. Director, Content and Thought LeadershipJoveopr@ in to access your portfolio
Business Wire
2 hours ago
- Business Wire
Single Pass Inc. Launches Global Post-Market Evaluation of the Biopsy Tract Closure Device
LAKE FOREST, Calif.--(BUSINESS WIRE)--Single Pass Inc., a medical technology innovator focused on improving procedural safety in biopsy care, today announced the launch and first enrollment in B-S.A.F.E. (Biopsy with SinglePass: Assessing Fast & Effective Tract Closure) – a global, post-FDA market evaluation to generate real-world evidence of the SinglePass™ electrocautery biopsy closure device. I use SinglePass on every visceral biopsy for both tumor and parenchyma, including kidney and liver! This innovative device efficiently seals biopsy channels, reducing bleeding risks and improving patient safety across all my biopsy procedures. Share Despite the millions of solid organ percutaneous biopsies performed successfully each year, unintended bleeding post-procedure is a real risk requiring additional procedures, longer hospital stays, and increased costs. And in rare instances, the complications can be devastating. The SinglePass device is designed to cauterize the biopsy tract immediately after tissue extraction, offering a novel approach to reduce bleeding complications, enhance procedural efficiency, and optimize patient observation time. 'Single Pass's global post-market evaluation - B-S.A.F.E. - reflects our commitment to innovation backed by evidence,' said John Zehren, CEO of Single Pass Inc. 'We're honored to work alongside frontline clinicians to validate real-world safety, usability, and performance, bringing an innovative solution for patients undergoing biopsy procedures.' B-S.A.F.E. is a multicenter post-market device evaluation that will assess reduction in post-biopsy bleeding and complications, post-biopsy observation time and workflow optimization. 'The SinglePass device represents a transformational advancement in the world of core needle biopsy,' said Dr. Alexander Misono, MD, MBA, RPVI, Chief of Interventional Radiology at Hoag Hospital Irvine in Irvine, CA. 'With the ability of SinglePass to provide immediate and reliable tract closure, we are already witnessing an inevitable shift in the way we manage bleeding risk and patient recovery. I'm proud to contribute to this evaluation and help drive the future standard of care.' "I use SinglePass on every visceral biopsy for both tumor and parenchyma, including kidney and liver!' remarked Dr. Francis Kang, Clinical Chief of Interventional Radiology at Robert Wood Johnson University Hospital in New Brunswick, NJ. 'This innovative device efficiently seals biopsy channels, significantly reducing bleeding risks and improving patient safety across all my biopsy procedures." For more information, visit About Single Pass Inc. Single Pass Inc. is a privately held medical device company dedicated to enhancing safety and workflow efficiency in image-guided biopsy procedures. Its flagship device, the SinglePass Electrocautery Biopsy Closure Device, enables clinicians to cauterize the biopsy tract in a single step, potentially improving patient outcomes and reducing procedural complexity. The company is headquartered in Lake Forest, California.
